Please assess the completion status of the following clinical trial:

Trial Title: mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have provided a signed Informed Consent Form~* ECOG performance status of 0-1~* BMI ≥ 18.5~* Age: 18-65 years old~* Histologically confirmed diagnosis of metastatic pancreatic cancer~* No prior palliative chemotherapy~* Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria~* Life expectancy ≥ 3 months~* Patient has adequate bone marrow and organ function~  * Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L~ * Platelets ≥ 90 x 109/L~ * Hemoglobin ≥ 90 g/L~* Patient has adequate liver function~  * AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis)~ * Serum bilirubin ≤ 1.2 x ULN~* Creatinine ≤ 1.25 times ULN~* Good compliance~Exclusion Criteria:~* Pregnant or lactating women~* Brain metastasis or only with bone metastasis.~* Patients with severe gastrointestinal hemorrhage which need frequent blood transfusions.~* Refuse to take appropriate contraceptive measures (including male patients).~* Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.~* Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases.~* Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ).~* Psychiatric illness that would prevent the patient from giving informed consent.~* Patient is concurrently using other antineoplastic agent~* Patient has used investigational antineoplastic agent within 4 weeks prior to entry.~* Known HIV-positivity.~* No history of chronic diarrhea, nausea or vomit.~* No ≥ grade 2 sensory peripheral neuropathy.~* A history of transmural myocardial infarction (within 6 months prior to entry), congestive heart failure, and unstable angina.~* Infectious disease or inflammation with body temperature ≥ 38 ℃.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- FOLFIRINOX (Type: EXPERIMENTAL): Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).